This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
In The Journal, February 11, appeared five communications on sulfapyridine. One was a report of the Council on Pharmacy and Chemistry in which the Council recommended that the preparation be not licensed for sale in interstate commerce at that time. Under the new food and drug act we have advanced greatly in the commercial introduction of new products. For the first time a preliminary survey of the potentiality for good and for harm preceded the exploitation of a drug. The medical profession had opportunity of being informed and its representatives consulted about the drug before any preparation was placed on the open market.
After the Council had published its preliminary report, much evidence was assembled. March 2 The Journal sent inquiries to all investigators who had clinical experience with the product during the period between its availability for experimental use and its introduction on the market. Replies were received from
SULFAPYRIDINE. JAMA. 1939;112(18):1833. doi:10.1001/jama.1939.02800180057019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: